| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.3 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |